Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
To plan ahead for inventory purposes
— Pharmacy purchaser, USA
To conduct research on drug patent expirations
— Data management / business information, specialty pharmaceuticals, China
To get yearly lists of patent expirations
— Analyst, Russia
To understand patent expirations of controlled substances
— Consulting, USA
To study crossover potential for veterinary medicine
— Chief medical officer, USA
Generated: May 23, 2017
Which drugs does patent 6,727,256 protect, and when does it expire?
| Title: | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| Abstract: | Substituted heteroaromatic compounds of formula (I), wherein X is N or CH; Y is CR.sup.1 and V is N; or Y is N and V is CR.sup.1 ; or Y is CR.sup.1 and V is CR.sup.2 ; or Y is CR.sup.2 and V is CR.sup.1 ; R.sup.1 represents a group CH.sub.3 SO.sub.2 CH.sub.2 CH.sub.2 NHCH.sub.2 --Ar--, wherein Ar is selected from phenyl, furan, thiophene, pyrrole and thiazole, each of which may optionally be substituted by one or two halo, C.sub.1-4 alkyl or C.sub.1-4 alkoxy groups; R.sup.2 is selected from the group comprising hydrogen, halo, hydroxy, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylamino and di[C.sub.1-4 alkyl]amino; U represents a phenyl, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl or 1H-benzotriazolyl group, substituted by an R.sup.3 group and optionally substituted by at least one independently selected R.sup.4 group; R.sup.3 is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl, or R.sup.3 represents trihalomethylbenzyl or trihalomethylbenzyloxy; or R.sup.3 represents a group of formula (a) wherein each R.sup.5 is independently selected from halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy; and n is 0 to 3; each R.sup.4 is independently hydroxy, halogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, C.sub.1-4 alkoxy, amino, C.sub.1-4 alkylamino, di[C.sub.1-4 alkyl]amino, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulphinyl, C.sub.1-4 alkylsulphonyl, C.sub.1-4 alkylcarbonyl, carboxy, carbamoyl, C.sub.1-4 alkoxycarbonyl, C.sub.1-4 alkanoylamino, N-(C.sub.1-4 alkyl)carbamoyl, N,N-di(C.sub.1-4 alkyl)carbamoyl, cyano, nitro and trifluoromethyl; and salts and solvates thereof, are disclosed, as are methods for their preparation, pharmaceutical compositions containing them and their use in medicine. |
| Inventor(s): | Carter; Malcolm Clive (Ware, GB), Cockerill; George Stuart (Bedford, GB), Guntrip; Stephen Barry (Hertford, GB), Lackey; Karen Elizabeth (Hillsborough, NC), Smith; Kathryn Jane (Bishop's Stortford, GB) |
| Assignee: | SmithKline Beecham Corporation (Philadelphia, PA) |
| Application Number: | 09/582,746 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Dosage form; Use; |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis Pharms Corp | TYKERB | lapatinib ditosylate | TABLET;ORAL | 022059-001 | Mar 13, 2007 | RX | Yes | Yes | 6,727,256 | ► Subscribe | Y | Y | TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB | ||||||||||||||||
Novartis Pharms Corp | TYKERB | lapatinib ditosylate | TABLET;ORAL | 022059-001 | Mar 13, 2007 | RX | Yes | Yes | 6,727,256 | ► Subscribe | Y | Y | TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR | ||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 9800569 | Jan 12, 1998 |
| PCT Information | |||
| PCT Filed | January 08, 1999 | PCT Application Number: | PCT/EP99/00048 |
| PCT Publication Date: | July 15, 1999 | PCT Publication Number: | WO99/35146 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,513,262 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | ► Subscribe | |||||||||||||||||||||||||||
| 6,713,485 | Heterocyclic compounds | ► Subscribe | |||||||||||||||||||||||||||
| 9,199,973 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | ► Subscribe | |||||||||||||||||||||||||||
| 8,912,205 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | ► Subscribe | |||||||||||||||||||||||||||
| 7,109,333 | Heterocyclic compounds | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 1446 | ► Subscribe | |||||||||||||||||||||||||||
| African Regional IP Organization (ARIPO) | 200001861 | ► Subscribe | |||||||||||||||||||||||||||
| Argentina | 015507 | ► Subscribe | |||||||||||||||||||||||||||
| Argentina | 066982 | ► Subscribe | |||||||||||||||||||||||||||
| Austria | 270670 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
To get information on pharmaceutical patents
— Business development, China
To find all manufacturers of a drug with active DMFs
— CEO, specialty pharmaceutical firm, USA
To obtain information on drug patents
— Biostatistician, India
Better understanding of company drug patent expirations for investing purposes
— Analyst, USA
To identify branded drug patent expiration and generic market entry
— CRO project manager, Portugal
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639
Follow DrugPatentWatch:
